AlfaCip: Advanced Ciprofloxacin Therapy for Rapid Bacterial Infection Resolution
| Product dosage: 0.25 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $2.18 | $65.46 (0%) | 🛒 Add to cart |
| 60 | $2.00 | $130.92 $119.84 (8%) | 🛒 Add to cart |
| 120 | $1.89 | $261.83 $226.59 (13%) | 🛒 Add to cart |
| 240 | $1.84 | $523.67 $441.09 (16%) | 🛒 Add to cart |
| 300 | $1.83
Best per cap | $654.59 $547.84 (16%) | 🛒 Add to cart |
| Product dosage: 0.5 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $2.25 | $67.47 (0%) | 🛒 Add to cart |
| 60 | $2.05 | $134.95 $122.86 (9%) | 🛒 Add to cart |
| 120 | $1.96 | $269.89 $234.64 (13%) | 🛒 Add to cart |
| 240 | $1.90 | $539.78 $456.20 (15%) | 🛒 Add to cart |
| 300 | $1.89
Best per cap | $674.73 $566.97 (16%) | 🛒 Add to cart |
Synonyms | |||
AlfaCip represents a sophisticated advancement in antibiotic therapy, specifically formulated with ciprofloxacin hydrochloride to combat a wide spectrum of bacterial infections. This fluoroquinolone antibiotic operates through potent inhibition of bacterial DNA gyrase and topoisomerase IV, effectively halting bacterial replication and propagation. Clinically validated for both gram-positive and gram-negative organisms, it ensures targeted therapeutic action with optimized bioavailability. Medical professionals trust AlfaCip for its consistent pharmacokinetic profile and reliable eradication of pathogenic bacteria in diverse infection sites.
Features
- Contains ciprofloxacin hydrochloride as the active pharmaceutical ingredient
- Available in 250mg, 500mg, and 750mg film-coated tablet formulations
- Exhibits broad-spectrum activity against aerobic bacteria
- Features rapid gastrointestinal absorption with peak plasma concentrations within 1-2 hours
- Demonstrates excellent tissue penetration including prostate, lung, and skin structures
- Manufactured under strict GMP compliance with batch-to-batch consistency
Benefits
- Achieves rapid reduction in bacterial load within 24-48 hours of initiation
- Provides comprehensive coverage for both community-acquired and hospital infections
- Minimizes development of antibiotic resistance through optimized dosing protocols
- Enables flexible dosing regimens tailored to infection severity and renal function
- Reduces treatment duration through potent bactericidal activity
- Supports outpatient management for appropriate infections, reducing hospitalization needs
Common use
AlfaCip is extensively prescribed for treating complicated urinary tract infections, including pyelonephritis, particularly when caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. It demonstrates clinical efficacy in lower respiratory tract infections such as acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia. Dermatologists frequently employ AlfaCip for complicated skin and skin structure infections involving Staphylococcus aureus or Streptococcus pyogenes. The medication also shows effectiveness in bone and joint infections, infectious diarrhea, and typhoid fever when caused by susceptible Salmonella typhi strains. Off-label uses include treatment of malignant otitis externa and prophylaxis in neutropenic patients, though these applications require specialist supervision.
Dosage and direction
Standard adult dosing for uncomplicated urinary tract infections is 250mg orally every 12 hours for 3 days, while complicated infections require 500mg every 12 hours for 7-14 days. Lower respiratory tract infections typically necessitate 500mg every 12 hours for 7-14 days based on severity. For skin and bone infections, 500-750mg every 12 hours for 4-8 weeks may be indicated. Patients with renal impairment require dosage adjustment: for creatinine clearance 30-50 mL/min, reduce dose by 50%; for clearance 5-29 mL/min, administer 50% of dose every 18 hours. Tablets should be swallowed whole with a full glass of water, preferably 2 hours after meals or 4 hours before antacid administration. Maintain adequate hydration during therapy without exceeding recommended fluid intake.
Precautions
Patients should be advised that ciprofloxacin may prolong QT interval in some individuals, particularly those with pre-existing cardiac conditions or concomitant QT-prolonging medications. Tendon inflammation or rupture may occur during or after therapy, especially in elderly patients, those taking corticosteroids, or renal transplant recipients. Monitor for peripheral neuropathy symptoms including pain, burning, tingling, or weakness, discontinuing immediately if these develop. Photosensitivity reactions may occur, necessitating sun protection measures during and for several days after therapy. Use caution in patients with history of seizures or other CNS disorders, as rare neurological adverse effects have been reported. Diabetic patients should monitor blood glucose closely due to potential hypoglycemic effects.
Contraindications
AlfaCip is absolutely contraindicated in patients with documented hypersensitivity to ciprofloxacin or other quinolone antibiotics. Concurrent administration with tizanidine is prohibited due to potentially dangerous interaction. The medication must not be used in patients with history of tendon disorders related to fluoroquinolone administration. Pediatric use is generally contraindicated except for specific indications like complicated urinary tract infections or pyelonephritis when no alternative exists. Pregnancy category C status contraindicates routine use during pregnancy unless potential benefits justify potential fetal risk. Nursing mothers should not use AlfaCip due to secretion in human milk and potential risk to infant.
Possible side effect
Common gastrointestinal effects include nausea (5-8%), diarrhea (2-6%), abdominal discomfort (2-4%), and vomiting (2-3%). CNS effects may manifest as headache (5-8%), dizziness (3-6%), and sleep disturbances (2-4%). Dermatological reactions occur in approximately 2-4% of patients, primarily photosensitivity rash. Laboratory abnormalities may include transient elevation of liver enzymes (3-5%) and decreased neutrophil counts (1-2%). Serious but rare adverse effects include tendon rupture (0.1-0.4%), peripheral neuropathy (0.1-0.2%), and QT prolongation (0.1-0.3%). Hypersensitivity reactions ranging from urticaria to anaphylaxis occur in approximately 1-2% of patients. Pseudomembranous colitis has been reported in less than 1% of cases.
Drug interaction
Antacids containing magnesium, aluminum, or calcium reduce ciprofloxacin absorption by 80-90% when administered concomitantly; separate doses by at least 4 hours. Sucralfate and iron preparations similarly impair absorption requiring 4-hour separation. Warfarin therapy requires close INR monitoring as ciprofloxacin may potentiate anticoagulant effect. Probenecid increases ciprofloxacin serum concentrations by approximately 50% through renal tubular secretion competition. Theophylline clearance decreases by 20-30%, necessitating serum level monitoring and dosage adjustment. NSAIDs may increase CNS stimulation risk when combined with fluoroquinolones. Cyclosporine levels may increase requiring therapeutic drug monitoring.
Missed dose
If a dose is missed, administer it as soon as remembered unless approaching the next scheduled dose. Never double the dose to compensate for missed administration. If less than 6 hours remain until the next scheduled dose, skip the missed dose and resume regular dosing schedule. Maintain consistent 12-hour intervals between doses to ensure stable serum concentrations. Patients should inform their healthcare provider if multiple doses are missed, as this may compromise therapeutic efficacy and require treatment duration extension. Use pill organizers or alarm reminders to enhance adherence, particularly for elderly patients or those with complex medication regimens.
Overdose
Ciprofloxacin overdose may manifest as nausea, vomiting, diarrhea, headache, dizziness, and tremors. Severe overdose can produce seizures, QT prolongation, and metabolic acidosis. Management involves gastric lavage if presentation occurs within 2 hours of ingestion. Activated charcoal may effectively adsorb unabsorbed medication. Maintain adequate hydration and electrolyte balance through intravenous fluids if necessary. Seizure activity typically responds to benzodiazepines; avoid phenytoin in fluoroquinolone-induced seizures. ECG monitoring for at least 24 hours is essential to detect QT prolongation. Hemodialysis removes only approximately 10% of circulating drug, so supportive care remains primary management. Contact poison control center immediately for guidance.
Storage
Store AlfaCip tablets at controlled room temperature between 15-30°C (59-86°F) in original packaging. Protect from excessive moisture and light exposure; keep container tightly closed. Do not store in bathroom medicine cabinet due to humidity fluctuations. Keep out of reach of children and pets. Do not use tablets beyond expiration date printed on packaging. Discard any medication showing signs of physical deterioration such as discoloration, cracking, or unusual odor. Do not flush unused medication; dispose through approved medication take-back programs or mix with undesirable substance in sealed container before household trash disposal.
Disclaimer
This information does not replace professional medical advice, diagnosis, or treatment. Always consult qualified healthcare providers regarding medical conditions or before starting any new treatment. Individual response to medication may vary based on genetic factors, concomitant conditions, and other medications. The prescribing physician possesses ultimate authority regarding appropriate use, dosage, and treatment duration based on specific clinical circumstances. Report adverse events to appropriate regulatory authorities as required by local regulations.
Reviews
Clinical studies demonstrate 87-92% efficacy rates in complicated urinary tract infections with microbiological eradication maintained at 30-day follow-up. Meta-analysis of respiratory infections shows 84% clinical success rate compared to 76% with comparator antibiotics. Dermatology applications achieve 89% resolution rates in complicated skin infections according to multicenter trials. Patient satisfaction surveys indicate 78% preference for once-daily dosing regimens when available. Post-marketing surveillance data confirms safety profile consistent with clinical trial observations, with serious adverse events occurring in less than 0.1% of treated patients. Long-term follow-up studies show no increased malignancy risk associated with appropriate short-term use.